Developer docs
API playgroundTry for free, no card

Search company profiles

Dipharma

Full company profile

uuid000drgm

Namestring
Dipharma
Legal namestring
Dipharma Francis S.r.l.
Websiteurl
dipharma.com
Company typeenum
Private
Founded yearint
1949
Descriptiontext

Dipharma Francis S.r.l. is a third-generation family-owned Italian Contract Development and Manufacturing Organization (CDMO) and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company serves both innovator pharmaceutical companies (via custom synthesis/exclusive synthesis services for New Chemical Entities and difficult molecules such as heterocycles, small peptides, and natural products) and generic pharmaceutical companies (via a catalogue of generic APIs including Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). It operates four cGMP manufacturing sites across Italy (Baranzate HQ, Mereto di Tomba, Caronno Pertusella) and the USA (Kalamazoo, MI), supported by two R&D centers and approximately 600 employees. Reported group revenue stood at approximately €160 million as of 2024.

The company's technical positioning is rooted in its 1949 civil-explosives heritage, which seeded distinctive competencies in handling hazardous chemistry — high-pressure hydrogenation (up to 40 bar and 220°C), batch and continuous nitration, nitroesterification, and azide chemistry — developed in strategic partnership with Biazzi SA, the engineering firm that owns the related continuous nitroglycerin process invented by founder Dr. Mario Biazzi. A team of 80+ R&D professionals (predominantly Masters and PhDs) operates proprietary process and analytical capabilities including a 15N-NMR method for nitrosamine impurity detection published in Organic Process Research & Development. Manufacturing capacity was materially expanded in 2023 with a second cGMP kilolab line at the US site (reactors up to 105 L, tripling capacity), and the company has secured FDA, ANVISA, and EU regulatory qualifications.

Revenue mechanics are split across two streams: (a) CDMO/Exclusive Synthesis services sold on a project-by-project contract basis with scope, complexity, and regulatory requirements driving quote-based pricing, and (b) Catalogue APIs and intermediates supplied to generic manufacturers under license/qualification terms with regulatory filings (EU DMF, CEP, US DMF, ANVISA CBPF, CADIFA) acting as the qualification-driven moat. Go-to-market is enterprise field sales via regional offices (Europe, North America, Japan, Rest of World) supplemented by heavy participation in industry events (CPHI, ChemOutsourcing, BIO, DCAT). The company does not disclose specific pricing tiers publicly; all engagement is contact-based.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKalamazoo, United States
HQ citystring
Kalamazoo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, contract drug manufacturing, custom synthesis services, pharmaceutical intermediates, API development services
Industry7 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical API Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO/Exclusive Synthesis Services
TypeProfessional Services
Description

Contract development and manufacturing organization providing custom synthesis of difficult molecules, process route development and optimization, scale-up from early stage to commercial scale, analytical development, and solid state characterization services.

dipharma.com
2Generic APIs and Intermediates
TypeOne Time License
Description

Manufacturing and supply of catalog active pharmaceutical ingredients for generic market. Includes advanced intermediates for pharmaceutical customers worldwide.

dipharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dipharma is a CDMO and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for the pharmaceutical industry. It operates two business lines: Exclusive Synthesis (custom manufacturing of difficult molecules including heterocycles, small peptides, and natural products with process development and scale-up services from preclinical to commercial) and Catalogue APIs (portfolio of generic APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). The offering is supported by 4 cGMP manufacturing plants in Italy and the USA, two R&D centers, and proprietary hazardous chemistry capabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 20% reduction in greenhouse gas emissions over past 5 years
+2 more records
Product overview1 text field

Dipharma is a global Contract Development and Manufacturing Organization (CDMO) and leading manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company operates two core business lines: Exclusive Synthesis (custom synthesis/CDMO services) offering custom manufacturing of difficult molecules with process development and scale-up capabilities, and Catalogue APIs providing a portfolio of generic Active Pharmaceutical Ingredients. The offering is supported by cGMP manufacturing facilities including a Kilolab in Kalamazoo, MI (USA) and pilot plants in Italy (Mereto di Tomba and Caronno Pertusella), comprehensive R&D services from two fully-equipped R&D centers in Italy and USA, and technical white papers covering specialized topics such as nitrosamine risk control, azide chemistry, catalytic hydrogenation, and bile acid derivatives. Marketing collateral includes downloadable brochures for CDMO services and API portfolios.

Product and service6 records
1CDMO Services (Contract Development and Manufacturing Organization)
CategoryCDMO / Exclusive Synthesis
Description

Full-service Contract Development and Manufacturing Organization services offering custom synthesis, process route development, optimization, scale-up, and cGMP manufacturing of Active Pharmaceutical Ingredients from preclinical through commercial scale, for innovator and generic pharmaceutical companies.

2Exclusive Synthesis
CategoryCDMO / Exclusive Synthesis
Description

Custom synthesis services for difficult molecules including heterocycles, small peptides, and natural products, with process route development, optimization, scale-up to commercial scale, process impurity identification, safety assessment, and process chemistry re-design.

3Catalogue APIs (Generic APIs)
CategoryCatalogue APIs / Generic APIs
Description

Portfolio of generic Active Pharmaceutical Ingredients for the pharmaceutical market, including APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid, with regulatory dossier support including EU DMF, CEP, US DMF, and ANVISA certifications.

4cGMP Kilolab
CategoryManufacturing facility / Kilolab service
Description

Cutting-edge cGMP manufacturing suite located in Kalamazoo, MI (USA), providing API supply for clinical Phase 1 and early Phase 2, supported by a state-of-the-art cGMP Quality Control laboratory. FDA registered (FEI: 3004853226).

5cGMP Pilot Plants
CategoryManufacturing facility / Pilot plant service
Description

Small-scale cGMP pilot plants located at the Mereto di Tomba and Caronno Pertusella sites in Italy, offering full range of scale-up capabilities for early-stage drug development, clinical trials, and small production batches.

6R&D Services
CategoryResearch and Development Services
Description

Research and development services including process research, supply chain evaluation, analytical research, process development, and process industrialization, backed by a team of 80+ skilled professionals and two R&D centers in Italy and the USA.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Biazzi SA
Strategic tierCoreTypeTechnology or Integration
Description

Strategic cooperation with Biazzi SA, the engineering company that leads the market in development and optimization of niche technologies, special equipment, and high-performance manufacturing complexes worldwide. Biazzi is the reference company for explosives, nitration, and hydrogenation technologies. Dipharma has historically adopted Biazzi hydrogenation equipment for highly efficient patented technology delivering low impurity levels. This partnership is essential for Dipharma's technological growth in complex chemical manufacturing.

dipharma.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European CDMO with API manufacturing and drug delivery capabilities, owned by International Chemical Investors Group. Overlaps in complex peptide/small-molecule synthesis and specialty chemistry offerings.

TypeDirect peer
Description

Portuguese CDMO and API manufacturer with strong small-molecule process chemistry expertise and cGMP facilities in Europe, US and Asia. Direct competitor for custom synthesis and complex molecule development with similar hazardous chemistry capabilities.

TypeDirect peer
Description

Major European CDMO offering API manufacturing and finished dosage forms. Comparable as a mid-to-large private CDMO serving pharma customers across multiple regulatory jurisdictions.

TypeDirect peer
Description

European API manufacturer spun out from Sanofi, focused on generic APIs and CDMO services. Direct competitor in catalogue API supply with overlapping regulatory dossiers and customer relationships.

TypeDirect peer
Description

US-based CDMO specializing in small-molecule API development and manufacturing across clinical and commercial phases. Comparable scale, capabilities, and customer overlap with Dipharma's US operations.

TypeBroad incumbent
Description

China-based global CDMO for small molecules and APIs with massive scale and integrated discovery-to-commercial services. Sets global pricing/competitive benchmarks for the CDMO industry despite being a much larger player.

7Fareva
TypeBroad incumbent
Description

Large privately-held French CDMO providing API, drug product, and specialty manufacturing services across multiple dosage forms. Broader portfolio than Dipharma but overlapping in API manufacturing and CDMO services.

TypeDirect peer
Description

Global CDMO providing API development, manufacturing, and formulation services for small molecules. Comparable scale and service offering with strong CDMO focus on both innovator and generic customers.

9Olon Group
TypeDirect peer
Description

Italian-headquartered generic API manufacturer with global manufacturing footprint supplying generics and CDMO services. Strong overlap with Dipharma's catalogue API business and Italian operational base.

10Sequens
TypeDirect peer
Description

European specialty CDMO/API manufacturer focused on small-molecule APIs and custom synthesis. Comparable positioning as a mid-sized European API/CDMO competitor with regulatory expertise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dipharma

Pharmaceutical API Manufacturing (CDMO)dipharma.com

What Dipharma does

Dipharma Francis S.r.l. is a third-generation family-owned Italian Contract Development and Manufacturing Organization (CDMO) and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company serves both innovator pharmaceutical companies (via custom synthesis/exclusive synthesis services for New Chemical Entities and difficult molecules such as heterocycles, small peptides, and natural products) and generic pharmaceutical companies (via a catalogue of generic APIs including Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). It operates four cGMP manufacturing sites across Italy (Baranzate HQ, Mereto di Tomba, Caronno Pertusella) and the USA (Kalamazoo, MI), supported by two R&D centers and approximately 600 employees. Reported group revenue stood at approximately €160 million as of 2024.

The company's technical positioning is rooted in its 1949 civil-explosives heritage, which seeded distinctive competencies in handling hazardous chemistry — high-pressure hydrogenation (up to 40 bar and 220°C), batch and continuous nitration, nitroesterification, and azide chemistry — developed in strategic partnership with Biazzi SA, the engineering firm that owns the related continuous nitroglycerin process invented by founder Dr. Mario Biazzi. A team of 80+ R&D professionals (predominantly Masters and PhDs) operates proprietary process and analytical capabilities including a 15N-NMR method for nitrosamine impurity detection published in Organic Process Research & Development. Manufacturing capacity was materially expanded in 2023 with a second cGMP kilolab line at the US site (reactors up to 105 L, tripling capacity), and the company has secured FDA, ANVISA, and EU regulatory qualifications.

Revenue mechanics are split across two streams: (a) CDMO/Exclusive Synthesis services sold on a project-by-project contract basis with scope, complexity, and regulatory requirements driving quote-based pricing, and (b) Catalogue APIs and intermediates supplied to generic manufacturers under license/qualification terms with regulatory filings (EU DMF, CEP, US DMF, ANVISA CBPF, CADIFA) acting as the qualification-driven moat. Go-to-market is enterprise field sales via regional offices (Europe, North America, Japan, Rest of World) supplemented by heavy participation in industry events (CPHI, ChemOutsourcing, BIO, DCAT). The company does not disclose specific pricing tiers publicly; all engagement is contact-based.

Dipharma firmographics

Firmographics
Name
Dipharma
Legal name
Dipharma Francis S.r.l.
Website
https://dipharma.com
Company type
Private
Founded year
1949
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Dipharma industry classification

Industry
Product category
Pharmaceutical API Manufacturing (CDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)

Keywords

  • Active pharmaceutical ingredients
  • Contract drug manufacturing
  • Custom synthesis services
  • Pharmaceutical intermediates
  • API development services

Where Dipharma is headquartered

Location

Headquarters

HQ city
Kalamazoo
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Dipharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO/Exclusive Synthesis Services: Contract development and manufacturing organization providing custom synthesis of difficult molecules, process route development and optimization, scale-up from early stage to commercial scale, analytical development, and solid state characterization services.
  2. Generic APIs and Intermediates: Manufacturing and supply of catalog active pharmaceutical ingredients for generic market. Includes advanced intermediates for pharmaceutical customers worldwide.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Dipharma product offering

Product offering

Core offering

Dipharma is a CDMO and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for the pharmaceutical industry. It operates two business lines: Exclusive Synthesis (custom manufacturing of difficult molecules including heterocycles, small peptides, and natural products with process development and scale-up services from preclinical to commercial) and Catalogue APIs (portfolio of generic APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). The offering is supported by 4 cGMP manufacturing plants in Italy and the USA, two R&D centers, and proprietary hazardous chemistry capabilities.

Product overview

Dipharma is a global Contract Development and Manufacturing Organization (CDMO) and leading manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company operates two core business lines: Exclusive Synthesis (custom synthesis/CDMO services) offering custom manufacturing of difficult molecules with process development and scale-up capabilities, and Catalogue APIs providing a portfolio of generic Active Pharmaceutical Ingredients. The offering is supported by cGMP manufacturing facilities including a Kilolab in Kalamazoo, MI (USA) and pilot plants in Italy (Mereto di Tomba and Caronno Pertusella), comprehensive R&D services from two fully-equipped R&D centers in Italy and USA, and technical white papers covering specialized topics such as nitrosamine risk control, azide chemistry, catalytic hydrogenation, and bile acid derivatives. Marketing collateral includes downloadable brochures for CDMO services and API portfolios.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDMO Services (Contract Development and Manufacturing Organization) Full-service Contract Development and Manufacturing Organization services offering custom synthesis, process route development, optimization, scale-up, and cGMP manufacturing of Active Pharmaceutical Ingredients from preclinical through commercial scale, for innovator and generic pharmaceutical companies.
  • Exclusive Synthesis Custom synthesis services for difficult molecules including heterocycles, small peptides, and natural products, with process route development, optimization, scale-up to commercial scale, process impurity identification, safety assessment, and process chemistry re-design.
  • Catalogue APIs (Generic APIs) Portfolio of generic Active Pharmaceutical Ingredients for the pharmaceutical market, including APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid, with regulatory dossier support including EU DMF, CEP, US DMF, and ANVISA certifications.
  • cGMP Kilolab Cutting-edge cGMP manufacturing suite located in Kalamazoo, MI (USA), providing API supply for clinical Phase 1 and early Phase 2, supported by a state-of-the-art cGMP Quality Control laboratory. FDA registered (FEI: 3004853226).
  • cGMP Pilot Plants Small-scale cGMP pilot plants located at the Mereto di Tomba and Caronno Pertusella sites in Italy, offering full range of scale-up capabilities for early-stage drug development, clinical trials, and small production batches.
  • R&D Services Research and development services including process research, supply chain evaluation, analytical research, process development, and process industrialization, backed by a team of 80+ skilled professionals and two R&D centers in Italy and the USA.

Quantifiable outcome

  • 20% reduction in greenhouse gas emissions over past 5 years
  • +2 more outcomes

Companies that use Dipharma

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Dipharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Dipharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Biazzi SAcoreTechnology or IntegrationStrategic cooperation with Biazzi SA, the engineering company that leads the market in development and optimization of niche technologies, special equipment, and high-performance manufacturing complexes worldwide. Biazzi is the reference company for explosives, nitration, and hydrogenation technologies. Dipharma has historically adopted Biazzi hydrogenation equipment for highly efficient patented technology delivering low impurity levels. This partnership is essential for Dipharma's technological growth in complex chemical manufacturing.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Dipharma competitors and assessment

Company assessment

Direct peers

  • CordenPharma: European CDMO with API manufacturing and drug delivery capabilities, owned by International Chemical Investors Group. Overlaps in complex peptide/small-molecule synthesis and specialty chemistry offerings.
  • Hovione: Portuguese CDMO and API manufacturer with strong small-molecule process chemistry expertise and cGMP facilities in Europe, US and Asia. Direct competitor for custom synthesis and complex molecule development with similar hazardous chemistry capabilities.
  • Aenova Group: Major European CDMO offering API manufacturing and finished dosage forms. Comparable as a mid-to-large private CDMO serving pharma customers across multiple regulatory jurisdictions.
  • EuroAPI: European API manufacturer spun out from Sanofi, focused on generic APIs and CDMO services. Direct competitor in catalogue API supply with overlapping regulatory dossiers and customer relationships.
  • Cambrex: US-based CDMO specializing in small-molecule API development and manufacturing across clinical and commercial phases. Comparable scale, capabilities, and customer overlap with Dipharma's US operations.
  • Curia Global (formerly AMRI): Global CDMO providing API development, manufacturing, and formulation services for small molecules. Comparable scale and service offering with strong CDMO focus on both innovator and generic customers.
  • Olon Group: Italian-headquartered generic API manufacturer with global manufacturing footprint supplying generics and CDMO services. Strong overlap with Dipharma's catalogue API business and Italian operational base.
  • Sequens: European specialty CDMO/API manufacturer focused on small-molecule APIs and custom synthesis. Comparable positioning as a mid-sized European API/CDMO competitor with regulatory expertise.

Broad incumbents

  • WuXi STA (WuXi AppTec): China-based global CDMO for small molecules and APIs with massive scale and integrated discovery-to-commercial services. Sets global pricing/competitive benchmarks for the CDMO industry despite being a much larger player.
  • Fareva: Large privately-held French CDMO providing API, drug product, and specialty manufacturing services across multiple dosage forms. Broader portfolio than Dipharma but overlapping in API manufacturing and CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Dipharma social profiles

Digital presence

Dipharma compliance and trust

Trust signal

Compliance7 records

Dipharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dipharma leadership team

Management profile

Number of profiles

Profiles10 records

Dipharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Dipharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dipharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dipharma

What does Dipharma do?

Dipharma is a CDMO and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for the pharmaceutical industry. It operates two business lines: Exclusive Synthesis (custom manufacturing of difficult molecules including heterocycles, small peptides, and natural products with process development and scale-up services from preclinical to commercial) and Catalogue APIs (portfolio of generic APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). The offering is supported by 4 cGMP manufacturing plants in Italy and the USA, two R&D centers, and proprietary hazardous chemistry capabilities.

Is Dipharma a public or private company?

Dipharma is a private company. It is classified as family owned and is currently operating.

When was Dipharma founded?

Dipharma was founded in 1949. It employs 51 to 100 people.

Where is Dipharma based?

Dipharma is headquartered in Kalamazoo, United States, in the North America region.

How does Dipharma make money?

Two revenue lines are on record. CDMO/Exclusive Synthesis Services are the primary driver. The others are generic APIs and Intermediates.

Who are Dipharma's main competitors?

Direct peers on record are CordenPharma, Hovione, Aenova Group, EuroAPI, Cambrex, Curia Global (formerly AMRI), Olon Group and Sequens. Broad incumbents are WuXi STA (WuXi AppTec) and Fareva.

Does Dipharma have an API?

No public API is recorded for Dipharma.

What industry is Dipharma in?

Dipharma's product category is Pharmaceutical API Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals